Albany, NY -- (SBWIRE) -- 02/18/2020 -- Muscle Invasive Bladder Cancer Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Muscle Invasive Bladder Cancer Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. Bladder cancer is the ninth most commonly diagnosed cancer worldwide, with more than 380,000 new cases each year and more than 150,000 deaths per year, and an estimated male-female ratio of 3.8:1.0.
2. In 2019, an estimated 80,470 adults (61,700 men and 18,770 women) in the United States had been diagnosed with bladder cancer.
3. Bladder cancer mostly affects older people. Ninety per cent (90%) of people with bladder cancer are older than 55, and the average age people are diagnosed with bladder cancer is 73.

Key benefits of the report
1. Muscle Invasive Bladder Cancer market report covers a descriptive overview and comprehensive insight of the Muscle Invasive Bladder Cancer epidemiology and Muscle Invasive Bladder Cancer market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Muscle Invasive Bladder Cancer market report provides insights into the current and emerging therapies.
3. Muscle Invasive Bladder Cancer market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Muscle Invasive Bladder Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Muscle Invasive Bladder Cancer market.

Request for sample pages

"Females show a higher proportion of incidence of Muscle Invasive Bladder Cancer as compared to males in the 7MM."

Bladder cancer commences when cells in the inner lining of the bladder become abnormal that causes the cells to proliferate and divide out of control leading to a fatal outcome if radical treatment is not provided on time. The treatment regimen for bladder cancer depends on the extent to which the tumour cells spread across the body, along with the time it takes to spread. Bladder cancer includes various types of cancer with the most common type being transitional cell carcinoma, also called urothelial carcinoma. Although there are several approved therapies for bladder cancer such as Tecentriq (Atezolizumab), Imfinzi (Durvalumab), Balversa (Erdafitinib), however, there is no approved therapy for the disease. Muscle Invasive Bladder Cancer treatment paradigm involves Surgery, Chemotherapy, and Radiotherapy.

Several companies are working for the launch of new therapies to provide better corrective treatment to the patients, which can change the market outlook in the coming years. At present, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, NanOlogy and others are actively working toward the development of potential therapies in order to fulfil the unmet medical needs of the currently used therapeutics. The other factors that shall further expedite the growth of Muscle Invasive Bladder Cancer market include increasing morbidity rate due to Muscle Invasive Bladder Cancer and increasing awareness about available treatments during the forecast period (2020–2030). A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Muscle Invasive Bladder Cancer.

The launch of the emerging therapies is expected to significantly impact Muscle Invasive Bladder Cancer treatment scenario in the upcoming years:-
Drugs covered
1. Durvalumab
2. Pembrolizumab
3. Nivolumab

And many others
The key players in Muscle Invasive Bladder Cancer market are:

1. AstraZeneca
2. Merck Sharp & Dohme
3. Bristol-Myers Squibb

And many others

Table of contents
1. Report Introduction
2. Executive Summary
3. SWOT Analysis
4. Muscle Invasive Bladder Cancer Market Overview at a Glance
5. Muscle Invasive Bladder Cancer Disease Background and Overview
6. Muscle Invasive Bladder Cancer Epidemiology and Patient Population
7. Muscle Invasive Bladder Cancer Country-Wise Epidemiology
7.1. United States
7.2. EU-5
7.2.1. Germany
7.2.2. France
7.2.3. Italy
7.2.4. Spain
7.2.5. United Kingdom
7.3. Japan
8. Muscle Invasive Bladder Cancer Treatment & Medical Practices
9. Muscle Invasive Bladder Cancer Emerging Therapies
9.1. Key Cross Competition
9.2. Durvalumab: AstraZeneca
9.3. Pembrolizumab: Merck Sharp & Dohme
9.4. Nivolumab: Bristol-Myers Squibb
9.5. TAR-200:Taris Bio
12. Attribute Analysis
13. Muscle Invasive Bladder Cancer Market Size
14. 7MM Muscle Invasive Bladder Cancer Country-Wise Market Analysis
14.1. United States
14.2. Germany
14.3. France
14.4. Italy
14.5. Spain
14.6. United Kingdom
14.7. Japan
15. Market Access and Reimbursement
16. Market Drivers
17. Market Barriers
18. Appendix
19. Muscle Invasive Bladder Cancer Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight